109 related articles for article (PubMed ID: 3912232)
41. The 52-kDa estrogen-induced protein secreted by MCF7 cells is a lysosomal acidic protease.
Morisset M; Capony F; Rochefort H
Biochem Biophys Res Commun; 1986 Jul; 138(1):102-9. PubMed ID: 3527155
[TBL] [Abstract][Full Text] [Related]
42. Parasite killing in Plasmodium vivax malaria by nitric oxide: implication of aspartic protease inhibition.
Sharma A; Eapen A; Subbarao SK
J Biochem; 2004 Sep; 136(3):329-34. PubMed ID: 15598889
[TBL] [Abstract][Full Text] [Related]
43. Thermodynamics and proton uptake for pepstatin binding to retroviral and eukaryotic aspartic proteases.
Xie D; Gulnik S; Collins L; Gustchina E; Bhat TN; Erickson JW
Adv Exp Med Biol; 1998; 436():381-6. PubMed ID: 9561245
[No Abstract] [Full Text] [Related]
44. Leucocyte migration inhibition in vitro with inhibitors of aspartic and sulphhydryl proteinases.
Lauritzen E; Møller S; Leerhoy J
Acta Pathol Microbiol Immunol Scand C; 1984 Apr; 92(2):107-12. PubMed ID: 6203330
[TBL] [Abstract][Full Text] [Related]
45. Structure and mechanism of the pepsin-like family of aspartic peptidases.
Dunn BM
Chem Rev; 2002 Dec; 102(12):4431-58. PubMed ID: 12475196
[No Abstract] [Full Text] [Related]
46. Localization and characterization of hemoglobin-degrading aspartic proteinases from the malarial parasite Plasmodium falciparum.
vander Jagt DL; Hunsaker LA; Campos NM; Scaletti JV
Biochim Biophys Acta; 1992 Aug; 1122(3):256-64. PubMed ID: 1504087
[TBL] [Abstract][Full Text] [Related]
47. A new type of aspartic proteinase inhibitors with a symmetric structure.
Tarasova NI; Gulnik SV; Prischenko AA; Livantsov MV; Lysogorskaya EN; Oksenoit ES
Adv Exp Med Biol; 1991; 306():539-42. PubMed ID: 1812755
[No Abstract] [Full Text] [Related]
48. Crystal structures of rhizopuspepsin/inhibitor complexes.
Parris KD; Hoover DJ; Davies DR
Adv Exp Med Biol; 1991; 306():217-31. PubMed ID: 1812709
[No Abstract] [Full Text] [Related]
49. Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles.
Bursavich MG; Rich DH
J Med Chem; 2002 Jan; 45(3):541-58. PubMed ID: 11806706
[No Abstract] [Full Text] [Related]
50. Purification and properties of three intracellular proteinases from Candida albicans.
Portillo F; Gancedo C
Biochim Biophys Acta; 1986 Apr; 881(2):229-35. PubMed ID: 3513844
[TBL] [Abstract][Full Text] [Related]
51. Subsite preferences of pepstatin-insensitive carboxyl proteinases from prokaryotes: kumamolysin, a thermostable pepstatin-insensitive carboxyl proteinase.
Oda K; Ogasawara S; Oyama H; Dunn BM
J Biochem; 2000 Sep; 128(3):499-507. PubMed ID: 10965051
[TBL] [Abstract][Full Text] [Related]
52. Purification and characterization of a hemoglobin degrading aspartic protease from the malarial parasite Plasmodium vivax.
Sharma A; Eapen A; Subbarao SK
J Biochem; 2005 Jul; 138(1):71-8. PubMed ID: 16046450
[TBL] [Abstract][Full Text] [Related]
53. Kinetic and mechanistic analysis of the association and dissociation of inhibitors interacting with secreted aspartic acid proteases 1 and 2 from Candida albicans.
Backman D; Danielson UH
Biochim Biophys Acta; 2003 Mar; 1646(1-2):184-95. PubMed ID: 12637026
[TBL] [Abstract][Full Text] [Related]
54. Crystal structure of aspartic proteinase from Irpex lacteus in complex with inhibitor pepstatin.
Fujimoto Z; Fujii Y; Kaneko S; Kobayashi H; Mizuno H
J Mol Biol; 2004 Aug; 341(5):1227-35. PubMed ID: 15321718
[TBL] [Abstract][Full Text] [Related]
55. Adaptation of the behaviour of an aspartic proteinase inhibitor by relocation of a lysine residue by one helical turn.
Winterburn TJ; Wyatt DM; Phylip LH; Berry C; Bur D; Kay J
Biol Chem; 2006 Aug; 387(8):1139-42. PubMed ID: 16895485
[TBL] [Abstract][Full Text] [Related]
56. The interaction of aspartic proteinases with naturally-occurring inhibitors from actinomycetes and Ascaris lumbricoides.
Valler MJ; Kay J; Aoyagi T; Dunn BM
J Enzyme Inhib; 1985; 1(1):77-82. PubMed ID: 3916913
[No Abstract] [Full Text] [Related]
57. Theoretical models of aspartic proteases: active site properties, dimer stability and interactions with model inhibitors.
Rayan A; Fliess A; Kotler M; Chorev M; Goldblum A
Adv Exp Med Biol; 1991; 306():555-8. PubMed ID: 1812758
[No Abstract] [Full Text] [Related]
58. The selectivity of statine-based inhibitors against various human aspartic proteinases.
Jupp RA; Dunn BM; Jacobs JW; Vlasuk G; Arcuri KE; Veber DF; Perlow DS; Payne LS; Boger J; de Laszlo S
Biochem J; 1990 Feb; 265(3):871-8. PubMed ID: 2407237
[TBL] [Abstract][Full Text] [Related]
59. No role for pepstatin-A-sensitive acidic proteinases in reovirus infections of L or MDCK cells.
Kothandaraman S; Hebert MC; Raines RT; Nibert ML
Virology; 1998 Nov; 251(2):264-72. PubMed ID: 9837790
[TBL] [Abstract][Full Text] [Related]
60. Proteases universally recognize beta strands in their active sites.
Tyndall JD; Nall T; Fairlie DP
Chem Rev; 2005 Mar; 105(3):973-99. PubMed ID: 15755082
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
